Elevated N1-Acetylspermidine Levels in Doxorubicin-treated MCF-7 Cancer Cells: Histone Deacetylase 10 Inhibition with an N1-Acetylspermidine Mimetic

Overview

Journal J Cancer Prev

Specialty Oncology

Date 2024 Jul 3

PMID 38957589

Authors

Ajay Kumar Raj

Kiran Bharat Lokhande

Kratika Khunteta

Sachin Chakradhar Sarode

Nilesh Kumar Sharma

Affiliations

Soon will be listed here.

Abstract

Cancer drug resistance is associated with metabolic adaptation. Cancer cells have been shown to implicate acetylated polyamines in adaptations during cell death. However, exploring the mimetic of acetylated polyamines as a potential anticancer drug is lacking. We performed intracellular metabolite profiling of human breast cancer MCF-7 cells treated with doxorubicin (DOX), a well known anticancer drug. A novel and in-house vertical tube gel electrophoresis assisted procedure followed by LC-HRMS analysis was employed to detect acetylated polyamines such as N1-acetylspermidine. We designed a mimetic N1-acetylspermidine (MINAS) which is a known substrate of histone deacetylase 10 (HDAC10). Molecular docking and molecular dynamics (MDs) simulations were used to evaluate the inhibitory potential of MINAS against HDAC10. The inhibitory potential and the ADMET profile of MINAS were compared to a known HDAC10 inhibitor Tubastatin A. N1-acetylspermidine, an acetylated form of polyamine, was detected intracellularly in MCF-7 cells treated with DOX over DMSO-treated MCF-7 cells. We designed and curated MINAS (PubChem CID 162679241). Molecular docking and MD simulations suggested the strong and comparable inhibitory potential of MINAS (-8.2 kcal/mol) to Tubastatin A (-8.4 kcal/mol). MINAS and Tubastatin A share similar binding sites on HDAC10, including Ser138, Ser140, Tyr183, and Cys184. Additionally, MINAS has a better ADMET profile compared to Tubastatin A, with a high MRTD value and lower toxicity. In conclusion, the data show that N1-acetylspermidine levels rise during DOX-induced breast cancer cell death. Additionally, MINAS, an N1-acetylspermidine mimetic compound, could be investigated as a potential anticancer drug when combined with chemotherapy like DOX.

References

Ou Y, Wang S, Li D, Chu B, Gu W . Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. Proc Natl Acad Sci U S A. 2016; 113(44):E6806-E6812. PMC: 5098629. DOI: 10.1073/pnas.1607152113. View

Tamari K, Konno M, Asai A, Koseki J, Hayashi K, Kawamoto K . Polyamine flux suppresses histone lysine demethylases and enhances expression in cancer stem cells. Cell Death Discov. 2018; 4:104. PMC: 6234213. DOI: 10.1038/s41420-018-0117-7. View

Kumar A, Patel S, Bhatkar D, Sarode S, Sharma N . A novel method to detect intracellular metabolite alterations in MCF-7 cells by doxorubicin induced cell death. Metabolomics. 2021; 17(1):3. DOI: 10.1007/s11306-020-01755-2. View

Vrijsen S, Besora-Casals L, van Veen S, Zielich J, Van den Haute C, Hamouda N . ATP13A2-mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress. Proc Natl Acad Sci U S A. 2020; 117(49):31198-31207. PMC: 7733819. DOI: 10.1073/pnas.1922342117. View

Murray-Stewart T, Woster P, Casero Jr R . Targeting polyamine metabolism for cancer therapy and prevention. Biochem J. 2016; 473(19):2937-53. PMC: 5711482. DOI: 10.1042/BCJ20160383. View

Navarro C, Ortega A, Santeliz R, Garrido B, Chacin M, Galban N . Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches. Pharmaceutics. 2022; 14(6). PMC: 9227908. DOI: 10.3390/pharmaceutics14061303. View

Manni A, Grove R, Kunselman S, Aldaz C . Involvement of the polyamine pathway in breast cancer progression. Cancer Lett. 1995; 92(1):49-57. DOI: 10.1016/0304-3835(95)03763-m. View

Wikoff W, Hanash S, DeFelice B, Miyamoto S, Barnett M, Zhao Y . Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B. J Clin Oncol. 2015; 33(33):3880-6. PMC: 4652011. DOI: 10.1200/JCO.2015.61.7779. View

Hsieh Y, Tu H, Pan S, Liou J, Yang C . Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo. Biochim Biophys Acta Mol Cell Res. 2019; 1866(6):992-1003. DOI: 10.1016/j.bbamcr.2019.03.003. View

10.

Halma M, Tuszynski J, Marik P . Cancer Metabolism as a Therapeutic Target and Review of Interventions. Nutrients. 2023; 15(19). PMC: 10574675. DOI: 10.3390/nu15194245. View

11.

Li Y, Seto E . HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med. 2016; 6(10). PMC: 5046688. DOI: 10.1101/cshperspect.a026831. View

12.

Iwata S, Sato Y, Asada M, Takagi M, Tsujimoto A, Inaba T . Anti-tumor activity of antizyme which targets the ornithine decarboxylase (ODC) required for cell growth and transformation. Oncogene. 1999; 18(1):165-72. DOI: 10.1038/sj.onc.1202275. View

13.

Patra S, Elahi N, Armorer A, Arunachalam S, Omala J, Hamid I . Mechanisms Governing Metabolic Heterogeneity in Breast Cancer and Other Tumors. Front Oncol. 2021; 11:700629. PMC: 8495201. DOI: 10.3389/fonc.2021.700629. View

14.

Wang C, Lin Y, Zhu H, Zhou Y, Mao F, Huang X . Efficacy and Safety Profile of Histone Deacetylase Inhibitors for Metastatic Breast Cancer: A Meta-Analysis. Front Oncol. 2022; 12:901152. PMC: 9192957. DOI: 10.3389/fonc.2022.901152. View

15.

Kuwata G, Hiramatsu K, Samejima K, Iwasaki K, Takahashi K, Koizumi K . Increase of N1, N12-diacetylspermine in tissues from colorectal cancer and its liver metastasis. J Cancer Res Clin Oncol. 2013; 139(6):925-32. DOI: 10.1007/s00432-013-1405-5. View

16.

Cheng F, Zheng B, Wang J, Zhao G, Yao Z, Niu Z . Histone deacetylase 10, a potential epigenetic target for therapy. Biosci Rep. 2021; 41(6). PMC: 8182986. DOI: 10.1042/BSR20210462. View

17.

Schyman P, Liu R, Desai V, Wallqvist A . vNN Web Server for ADMET Predictions. Front Pharmacol. 2017; 8:889. PMC: 5722789. DOI: 10.3389/fphar.2017.00889. View

18.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

19.

Geraldy M, Morgen M, Sehr P, Steimbach R, Moi D, Ridinger J . Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated. J Med Chem. 2019; 62(9):4426-4443. DOI: 10.1021/acs.jmedchem.8b01936. View

20.

Li Y, Zhang X, Zhu S, Dejene E, Peng W, Sepulveda A . HDAC10 Regulates Cancer Stem-Like Cell Properties in KRAS-Driven Lung Adenocarcinoma. Cancer Res. 2020; 80(16):3265-3278. PMC: 7442594. DOI: 10.1158/0008-5472.CAN-19-3613. View